Charles Schwab Investment Management Inc Uro Gen Pharma Ltd. Transaction History

Charles Schwab Investment Management Inc

$601 Billion
Q3 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 91,059 shares of URGN stock, worth $2.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

91,059

Previous 92,898 1.98%

Holding current value

$2.22 Million

Previous $1.27 Million 39.7%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	SELL	$12.96 - $21.42 $23,833 - $39,391	-1,839 Reduced 1.98%	91,059 $1.78 Million
Q2 2025 Aug 12, 2025	SELL	$3.9 - $15.46 $2,531 - $10,033	-649 Reduced 0.69%	92,898 $1.27 Million
Q1 2025 Sep 15, 2025	BUY	$9.27 - $12.13 $6,016 - $7,872	649 Added 0.7%	93,547 $1.03 Million
Q1 2025 May 09, 2025	BUY	$9.27 - $12.13 $278 - $363	30 Added 0.03%	93,547 $1.03 Million
Q4 2024 Feb 06, 2025	BUY	$10.52 - $13.11 $31,812 - $39,644	3,024 Added 3.34%	93,517 $995,000

Q3 2024 Nov 12, 2024	BUY	$12.7 - $17.92 $96,215 - $135,761	7,576 Added 9.14%	90,493 $1.15 Million
Q2 2024 Aug 12, 2024	BUY	$12.72 - $19.2 $254,870 - $384,710	20,037 Added 31.87%	82,917 $1.39 Million
Q4 2023 Feb 06, 2024	BUY	$10.87 - $15.93 $179,202 - $262,621	16,486 Added 35.53%	62,880 $943,000
Q3 2023 Nov 08, 2023	BUY	$8.84 - $22.64 $14,762 - $37,808	1,670 Added 3.73%	46,394 $649,000
Q2 2023 Aug 09, 2023	BUY	$8.75 - $14.29 $391,335 - $639,105	44,724 New	44,724 $462,000
Q2 2022 Aug 15, 2022	SELL	$5.12 - $8.74 $218,567 - $373,101	-42,689 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$14.31 - $18.39 $31,109 - $39,979	2,174 Added 5.37%	42,689 $719,000
Q2 2021 Aug 16, 2021	SELL	$15.2 - $20.94 $5,137 - $7,077	-338 Reduced 0.83%	40,515 $619,000
Q1 2021 May 17, 2021	SELL	$17.99 - $26.96 $3,292 - $4,933	-183 Reduced 0.45%	40,853 $796,000
Q4 2020 Feb 16, 2021	BUY	$17.54 - $25.43 $18,697 - $27,108	1,066 Added 2.67%	41,036 $740,000
Q3 2020 Nov 13, 2020	SELL	$18.81 - $26.42 $34,347 - $48,242	-1,826 Reduced 4.37%	39,970 $772,000
Q2 2020 Aug 14, 2020	BUY	$16.5 - $29.7 $20,328 - $36,590	1,232 Added 3.04%	41,796 $1.09 Million
Q1 2020 May 15, 2020	BUY	$13.68 - $34.6 $2,872 - $7,266	210 Added 0.52%	40,564 $724,000
Q4 2019 Feb 07, 2020	BUY	$21.11 - $34.86 $24,677 - $40,751	1,169 Added 2.98%	40,354 $1.35 Million
Q3 2019 Nov 08, 2019	BUY	$23.83 - $36.44 $4,956 - $7,579	208 Added 0.53%	39,185 $934,000
Q2 2019 Aug 09, 2019	BUY	$32.75 - $40.35 $1.28 Million - $1.57 Million	38,977 New	38,977 $1.4 Million

Others Institutions Holding URGN

# of Institutions

171

Shares Held

43.8M

Call Options Held

1.61M

Put Options Held

433K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $553M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Uro Gen Pharma Ltd. Transaction History